AEOLUS PHARMACEUTICALS
Mission Viejo
About AEOLUS PHARMACEUTICALS
Aeolus Pharmaceuticals is developing its lead compound, AEOL-10150, as a treatment for the pulmonary and delayed effects of acute radiation exposure (“Lung-ARS” and “DEARE”). The Company’s development work is funded under a five year, $118 million, cost-plus contract with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services. BARDA is the Federal agency in charge of contracting for advanced development of drugs to treat radiological, biological and chemical threats for the civilian population. BARDA also manages the $2.8BB Special Reserve Fund for the purchase of these drugs for the U.S. Strategic National Stockpile.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $18.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2015)
- Ticker: otcqb:AOLS
- Website: aolsrx.com
- Phone: +1 949-481-9825
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/aeolus-pharmaceuticals-1728028 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.